Lombard Odier Asset Management USA Corp Sells 1,589,047 Shares of Silence Therapeutics PLC Sponsored ADR $SLN

Posted by on Jun 17th, 2026

Lombard Odier Asset Management USA Corp reduced its stake in Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN – Free Report) by 86.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 255,901 shares of the company’s stock after selling 1,589,047 shares during the period. Lombard Odier Asset Management USA Corp owned approximately 0.54% of Silence Therapeutics worth $1,556,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. EHP Funds Inc. bought a new stake in shares of Silence Therapeutics in the third quarter valued at approximately $55,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Silence Therapeutics by 65.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock valued at $83,000 after buying an additional 5,421 shares during the period. Massar Capital Management LP bought a new stake in shares of Silence Therapeutics in the second quarter valued at approximately $115,000. Citadel Advisors LLC bought a new stake in shares of Silence Therapeutics in the third quarter valued at approximately $112,000. Finally, Jane Street Group LLC bought a new stake in shares of Silence Therapeutics in the fourth quarter valued at approximately $177,000. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Price Performance

NASDAQ SLN opened at $6.71 on Wednesday. The business has a fifty day moving average price of $6.74 and a two-hundred day moving average price of $6.10. Silence Therapeutics PLC Sponsored ADR has a fifty-two week low of $4.19 and a fifty-two week high of $8.40. The stock has a market capitalization of $316.98 million, a PE ratio of -4.22 and a beta of 1.48.

Silence Therapeutics (NASDAQ:SLN – Get Free Report) last released its earnings results on Friday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.14). Silence Therapeutics had a negative return on equity of 105.34% and a negative net margin of 8,943.86%.The business had revenue of $0.42 million for the quarter, compared to the consensus estimate of $1.26 million. As a group, sell-side analysts expect that Silence Therapeutics PLC Sponsored ADR will post -0.95 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on SLN shares. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, March 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a research note on Tuesday, April 21st. Jefferies Financial Group upgraded Silence Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Friday, March 13th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $55.00.

View Our Latest Report on Silence Therapeutics

About Silence Therapeutics

(Free Report)

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.

Featured Stories

Want to see what other hedge funds are holding SLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN – Free Report).

Institutional Ownership by Quarter for Silence Therapeutics (NASDAQ:SLN)

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.